Search - tctmd.com

Displaying 21 - 40 of 82

Sort: Relevancy | Date

AHA Selects 2023’s Leading Cardiovascular Research

News Daily News

AHA Selects 2023’s Leading Cardiovascular Research

December 22, 2023

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

News Daily News

New AF Guideline Emphasizes Early Rhythm Control, Elevates Ablation and LAAO

November 30, 2023

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

News Daily News

Asundexian’s Lack of Efficacy Sinks OCEANIC-AF

November 20, 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

News Conference News AHA 2023

Etripamil Nasal Spray Shows Promise for AF Patients With Rapid Ventricular Rate

November 16, 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presentation AHA 2023

The Artesia trial: Apixaban for Stroke Prevention in Subclinical Atrial Fibrillation

Presenter: Jeff Healey

November 16, 2023

Presentation AHA 2023

AZALEA-TIMI 71

Presenter: Christian T. Ruff

November 15, 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial -

Presentation AHA 2023

Efficacy and safety of anticoagulation with edoxaban in patients with Atrial high rate-episodes (AHRE) durations ≥ 24 hours - The NOAH-AFNET 6 trial

Presenter: Nina Becher

November 14, 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

News Conference News AHA 2023

Simultaneous Dual Cardioversion of AF Lessens Failure Rates in Obese Patients

November 14, 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

News Conference News AHA 2023

Large Study Affirms Safety of Pulsed-Field Ablation, Reveals Some Rare Complications

November 13, 2023

AZALEA-TIMI 71: Abelacimab Slashes Bleeds vs Rivaroxaban in AF, but Stroke Impact Unclear

News Conference News AHA 2023

NOW PUBLISHED - AZALEA-TIMI 71: Bleeds Plunge With Abelacimab vs Rivaroxaban in AF, but Stroke Impact Unclear

November 12, 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

News Conference News AHA 2023

ARTESiA: Apixaban Lowers Stroke Risk in Subclinical AF

November 12, 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

News Conference News AHA 2023

Off-label DOAC Dosing Common in Hospitalized AF Patients, Too

November 07, 2023

Acute AF Can Recur: Manage and Monitor Long-term, Says AHA

News Daily News

Acute AF Can Recur: Manage and Monitor Long-term, Says AHA

Michael O'Riordan

March 16, 2023

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

News Conference News AHA 2022

Botulinum Toxin Injections No Help for Postoperative AF: NOVA

Yael L. Maxwell

November 07, 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

News Conference News AHA 2022

First-line Ablation Reduces AF Progression, Boosts Quality of Life

November 07, 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

News Conference News AHA 2022

Atrial Fibrosis Mediated by Gum Disease May Be Missing AF Link

November 01, 2022

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

News Daily News

Exercise Keeps Athletic Heart Supple, Strong, Healthy: JACC Deep Dive

Michael O'Riordan

September 09, 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

News Conference News ACC 2022

Leaks After LAA Occlusion Tied to Uptick in Thromboembolic Events

April 04, 2022

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

News Conference News AHA 2021

Lariat LAA Ligation Doesn’t Boost Effect of AF Ablation: aMAZE Trial

November 18, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.